|

Pemetrexed + Cisplatin /Carboplatin Clinical Trials

4 actively recruiting trials across 3 locations

▲ +2 trials since August 2026

Also known as: Platinum-based chemotherapy doublet

Pipeline

Phase 1: 1Phase 3: 2Phase 2/3: 1

Top Sponsors

  • Revolution Medicines, Inc.1
  • Jiangsu Aosaikang Pharmaceutical Co., Ltd.1
  • Eikon Therapeutics1
  • Alterome Therapeutics, Inc.1

Indications

  • Lung Cancer4
  • Cancer4
  • Non Small Cell Lung Cancer (Squamous or Non Squamous)1
  • Stage 4 NSCLC1
  • Metastatic NSCLC - Non-Small Cell Lung Cancer1

Other1 trial

ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy
Phase 3

Daphne, Alabama1 trial

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

Southern Cancer Center, P.C.

Phase 2/3

Orlando, Florida1 trial

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

Research Site

Phase 1

Plantation, Florida1 trial

Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC

Florida Clinical Trials Group, LLC

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.